Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP512167.RAbfs5CaQLiFcbNjGIYZ7IPQ-YHvtdpuiXXwF9wBUAG0k130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP512167.RAbfs5CaQLiFcbNjGIYZ7IPQ-YHvtdpuiXXwF9wBUAG0k130_assertion type Assertion NP512167.RAbfs5CaQLiFcbNjGIYZ7IPQ-YHvtdpuiXXwF9wBUAG0k130_head.
- NP512167.RAbfs5CaQLiFcbNjGIYZ7IPQ-YHvtdpuiXXwF9wBUAG0k130_assertion description "[Complex karyotypes are seen in approximately 15% of de novo MDS/AML and in up to 50% of therapy-related MDS/AML.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP512167.RAbfs5CaQLiFcbNjGIYZ7IPQ-YHvtdpuiXXwF9wBUAG0k130_provenance.
- NP512167.RAbfs5CaQLiFcbNjGIYZ7IPQ-YHvtdpuiXXwF9wBUAG0k130_assertion evidence source_evidence_literature NP512167.RAbfs5CaQLiFcbNjGIYZ7IPQ-YHvtdpuiXXwF9wBUAG0k130_provenance.
- NP512167.RAbfs5CaQLiFcbNjGIYZ7IPQ-YHvtdpuiXXwF9wBUAG0k130_assertion SIO_000772 16142824 NP512167.RAbfs5CaQLiFcbNjGIYZ7IPQ-YHvtdpuiXXwF9wBUAG0k130_provenance.
- NP512167.RAbfs5CaQLiFcbNjGIYZ7IPQ-YHvtdpuiXXwF9wBUAG0k130_assertion wasDerivedFrom befree-2016 NP512167.RAbfs5CaQLiFcbNjGIYZ7IPQ-YHvtdpuiXXwF9wBUAG0k130_provenance.
- NP512167.RAbfs5CaQLiFcbNjGIYZ7IPQ-YHvtdpuiXXwF9wBUAG0k130_assertion wasGeneratedBy ECO_0000203 NP512167.RAbfs5CaQLiFcbNjGIYZ7IPQ-YHvtdpuiXXwF9wBUAG0k130_provenance.